Scinai Immunotherapeutics
SCNI
9 hedge funds and large institutions have $839K invested in Scinai Immunotherapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
17% more capital invested
Capital invested by funds: $717K → $839K (+$122K)
0% more funds holding
Funds holding: 9 → 9 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$260K |
| 2 |
Millennium Management
New York
|
+$108K |
| 3 |
VF
Virtu Financial
New York
|
+$25.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$51.9K |
| 2 |
Morgan Stanley
New York
|
-$1.38K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$617 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $704K | +$260K | +10,541 | +48% |
|
|
2
Millennium Management
New York
| $94K | +$108K | +4,360 | New |
|
|
VF
3
Virtu Financial
New York
| $23K | +$25.9K | +1,051 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $11.5K | +$12.4K | +502 | +1,673% |
|
|
5
Morgan Stanley
New York
| $4.88K | -$1.38K | -56 | -20% |
|
6
Credit Agricole
Montrouge Cedex,
France
| $916 | – | – | – |
|
|
APC
7
Aspire Private Capital
Cornelius,
North Carolina
| $346 | – | – | – |
|
|
GRP
8
Global Retirement Partners
San Rafael,
California
| $95 | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $43 | – | – | – |
|
|
NC
10
NewSquare Capital
Newtown Square,
Pennsylvania
| $4 | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$51.9K | -1,746 | Closed |
|
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$617 | -25 | Closed |
|
SCNI Hedge Fund Activity: Q1 2023 in Review
9 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2023, worth a combined $839K — up 17% from $717K a quarter earlier.
Fund positioning in SCNI was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, adding an estimated $260K. The largest seller was Citadel Advisors, exiting entirely with an estimated $51.9K sold.
- 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $839K of Scinai Immunotherapeutics stock for Q1 2023, up 17% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Scinai Immunotherapeutics buyer in Q1 2023 was Sabby Management, an estimated $260K added.
- The largest Scinai Immunotherapeutics seller in Q1 2023 was Citadel Advisors, an estimated $51.9K sold.
Based on aggregated 13F filings for Q1 2023.